XBRANE BIOPHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2035 SEK | +0.74% |
|
-2.16% | -97.96% |
| 02/05 | Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director | CI |
| 22/04 | Transcript : Xbrane Biopharma AB - Special Call |
Chart calendar Xbrane Biopharma AB
6ca90f7a30e3b86733ee8f9e39101e9.vnka03a3rj3ccSgzHdDly9-QwNfh_HRcRVzEWXilMsM.yjhumkTQnE2yG2EeJJ2hn4z1q5XVxBcKPQaAaD6XWIfME33-PsHHTuoGXw~478c92a5670c182186aa4deff07fe8fe
Upcoming events on Xbrane Biopharma AB
Past events on Xbrane Biopharma AB
| 02/05/2024 08:00 pm | Annual General Meeting |
| 20/03/2024 04:20 pm | Redeye Theme: Commercialization in Life Science |
| 26/02/2024 05:30 pm | Q4 2023 Earnings Call |
| 26/02/2024 12:30 pm | Q4 2023 Earnings Release |
| 22/02/2024 09:00 pm | Extraordinary Shareholders Meeting |
| 01/12/2023 03:30 am | Q3 2023 Earnings Call |
| 29/08/2023 12:30 pm | Q2 2023 Earnings Call |
| 29/08/2023 11:30 am | Q2 2023 Earnings Release |
| 31/05/2023 02:30 pm | Q1 2023 Earnings Call |
| 31/05/2023 11:30 am | Q1 2023 Earnings Release |
| 31/05/2023 09:30 am | ABGSC Life Science Summit |
| 04/05/2023 | Annual General Meeting |
| 16/03/2023 | BioStock Investor Meeting |
| 17/02/2023 02:30 pm | FY 2022 Earnings Call |
| 17/02/2023 12:30 pm | FY 2022 Earnings Release |
| 27/11/2022 | Redeye Life Science Day_Interview |
| 28/10/2022 05:30 pm | Q3 2022 Earnings Call |
| 28/10/2022 11:30 am | Q3 2022 Earnings Release |
| 22/09/2022 05:30 pm | Capital Markets Day |
| 20/09/2022 | Investor Meeting |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million SEK | Released Forecast Spread | 0,00 0,00 - | 0,00 6,60 - | 15,6 18,7 -16.88% | 57,6 65,0 -11.32% | 239 220 8.5% | 344 |
|
EBITDA Million SEK | Released Forecast Spread | -140 -113 -24.32% | -219 -198 -10.45% | -168 -224 24.84% | -150 -142 -5.38% | -288 -300 3.86% | -166 |
|
EBIT Million SEK | Released Forecast Spread | -165 -113 -45.68% | -225 -200 -12.57% | -181 -224 19.55% | -166 -152 -9.35% | -322 -316 -2.05% | -183 |
|
Earnings before Tax (EBT) Million SEK | Released Forecast Spread | -166 -113 -46.94% | -226 -201 -12.71% | -183 -225 18.6% | -169 -150 -12.56% | -322 -335 3.85% | -186 |
|
Net income Million SEK | Released Forecast Spread | -166 -83,0 -100.04% | -226 -201 -12.71% | -188 -225 16.32% | -173 -148 -16.69% | -388 -336 -15.57% | -186 |
|
EPS SEK | Released Forecast Spread | -14,8 -5,40 -174.81% | -12,5 -10,9 -15.02% | -7,77 -9,83 20.92% | -6,75 -5,62 -20.19% | -13,5 -11,7 -15.88% | -0,13 |
| Announcement Date | 28/02/20 | 26/02/21 | 24/02/22 | 17/02/23 | 26/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million SEK | Released Forecast Spread | 4,47 4,80 -6.95% | 7,19 5,00 43.8% | 15,6 5,00 212.62% | 13,9 49,0 -71.56% | 17,3 9,19 88.41% | 61,8 12,0 415.24% | 51,1 64,4 -20.68% | 58,9 52,6 12.06% | 66,9 50,6 32.3% | 57,7 | 110 | 75,0 | 90,1 |
|
EBITDA Million SEK | Released Forecast Spread | -28,2 -57,0 50.44% | -32,9 -66,0 50.15% | -28,4 -81,0 64.98% | -37,6 -37,0 -1.72% | -50,7 | -81,6 -81,5 -0.12% | -69,2 -85,5 19.01% | -61,0 | -18,5 | -49,5 | -46,5 | ||
|
EBIT Million SEK | Released Forecast Spread | -32,1 -57,5 44.08% | -36,8 -66,0 44.27% | -32,4 -81,0 60% | -42,0 -37,0 -13.49% | -55,0 | -88,6 -48,1 -84.15% | -89,7 -85,2 -5.24% | -86,5 -89,3 3.15% | -65,7 | -22,3 | -54,0 | -50,9 | |
|
Earnings before Tax (EBT) Million SEK | Released Forecast Spread | -32,9 -58,1 43.28% | -37,5 -66,0 43.16% | -33,1 -81,0 59.19% | -42,6 -37,0 -15.17% | -55,3 -36,5 -51.48% | -57,9 -35,0 -65.53% | -90,6 -48,8 -85.69% | -80,9 -89,5 9.53% | -92,6 -96,7 4.18% | -70,2 | -67,6 | -67,0 | -66,7 |
|
Net income Million SEK | Released Forecast Spread | -32,5 -58,1 44.07% | -36,1 -66,0 45.27% | -33,8 -81,0 58.3% | -41,9 -37,0 -13.2% | -60,7 -36,1 -68.41% | -58,4 -34,5 -69.32% | -91,0 -48,8 -86.57% | -81,2 -89,5 9.21% | -158 -96,7 -62.94% | -70,2 | -67,6 | -67,0 | -66,7 |
|
EPS SEK | Released Forecast Spread | -1,32 -2,32 43.06% | -1,44 -2,64 45.53% | -1,35 -3,25 58.41% | -1,67 -1,29 -29.43% | -2,25 -1,37 -64.25% | -2,12 -1,25 -69.08% | -3,22 -1,77 -81.56% | -2,78 -3,06 9.22% | -5,28 -3,31 -59.55% | -0,05 | -0,02 | -0,02 | -0,02 |
| Announcement Date | 24/02/22 | 05/05/22 | 22/07/22 | 28/10/22 | 17/02/23 | 31/05/23 | 29/08/23 | 30/11/23 | 26/02/24 | - | - | - | - |
| Today 10:30 am | VALNEVA: Q1 2024 Earnings Release |
| Today 04:30 pm | IONIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| Today 01:35 am | ABCELLERA BIOLOGICS INC.: Q1 2024 Earnings Release |
| 08/05/2024 | MIND MEDICINE (MINDMED) INC.: Q1 2024 Earnings Release |
| 08/05/2024 | BELITE BIO, INC: Q1 2024 Earnings Release (Projected) |
| 08/05/2024 | FORMYCON AG: Q1 2024 Earnings Release |
| 08/05/2024 | AN2 THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 08/05/2024 | CELLTRION, INC.: Q1 2024 Earnings Release (Projected) |
| 08/05/2024 | TANGO THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 08/05/2024 | VIRIDIAN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
Past sector events for Xbrane Biopharma AB
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- XBRANE Stock
- Calendar Xbrane Biopharma AB